Oral Anti-Diabetic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides), By End Users (Hospitals, Homecare, Speciality Centers, Others) By Region a
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationOral Anti-Diabetic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides), By End Users (Hospitals, Homecare, Speciality Centers, Others) By Region a
| Forecast Period | 2018-2028 |
| Market Size (2022) | USD 16.89 billion |
| CAGR (2023-2028) | 5.47% |
| Fastest Growing Segment | Hospitals |
| Largest Market | North America |
Market Overview
Key Market Drivers
Increasing Global Diabetes Prevalence
Advancements in Drug Formulations
Increasing Awareness and Diagnosis
Expanding Geriatric Population
Key Market Challenges
High Healthcare Costs
Side Effects and Safety Concerns
Medication Adherence
Key Market Trends
Personalized Medicine Approaches
Regulatory Support and Expedited Approvals
Innovations in Drug Formulations
Segmental Insights
Drugs Insights
Regional Insights
Recent Developments
- Zydus Lifesciences declared inJuly 2022 that it has been granted approval to market tablets of metforminhydrochloride and empagliflozin in various strengths. To enhance glycemiccontrol in individuals with type 2 diabetes mellitus, empagliflozin and metforminhydrochloride tablets are taken in conjunction with a healthy diet andexercise. In individuals with type 2 diabetes mellitus and establishedcardiovascular disease, they are also used to reduce the risk of cardiovasculardeath.
- In July 2022, GlenmarkPharmaceuticals Limited declared that sitagliptin and its Fixed DoseCombinations (FDCs) were now available in India for adults with Type 2diabetes. Under the brand name SITAZIT and its variations, Glenmark madeavailable eight alternative combinations of sitagliptin-based medications for areasonable price.
Key Market Players
- KONINKLIJKEPHILIPS N.V.
- SanofiS.A.
- EliLilly and Company
- AstraZeneca
- AstellasPharma Inc.
- Johnson& Johnson (Janssen Pharmaceuticals)
- BoehringerIngelheim
- MerckAnd Co.
- BristolMyers Squibb Company
- NovartisAG
| By Drugs | By End Users | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy